MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL

Cell Cycle

Volumn 13, Issue 5, 2014, Pages 834-844

  Van Der Linden, Marieke H ^a   Willekes, Merel ^a   Roon, Eddyvan ^a   Seslija, Lidija ^a   Schneider, Pauline ^a   Pieters, Rob ^a   Stam, Ronald W ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; CDK6; Infant; MLL rearrangement

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; HYBRID PROTEIN; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF4 FUSION PROTEIN; MLL ENL FUSION PROTEIN; PALBOCICLIB; PRB1 PROTEIN; PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EZH2 PROTEIN, HUMAN; MLL-AF4 FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; PRB1 PROTEIN, HUMAN; PROLINE RICH PROTEIN; PYRIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; INFANT DISEASE; LEUKEMIA CELL LINE; LEUKOCYTE; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; CELL CYCLE G1 PHASE; CELL FUSION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL FUSION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 6; G1 PHASE; HUMANS; INFANT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PIPERAZINES; POLYCOMB REPRESSIVE COMPLEX 2; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIDINES; SALIVARY PROLINE-RICH PROTEINS;

EID: 84898016920     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27757     Document Type: Article

References (51)

1. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia 1996; 10:372-7; PMID:8637251
2. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370:240-50; PMID:17658395; http://dx.doi.org/10.1016/S0140-6736(07)61126-X
3. Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013; 27:2165-76; PMID:23628958; http://dx.doi.org/10.1038/leu.2013.135
4. Jansen MW, Corral L, van der Velden VH, Panzer-Grümayer R, Schrappe M, Schrauder A, Marschalek R, Meyer C, den Boer ML, Hop WJ, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007; 21:633-41; PMID:17268512
5. van der Linden MH, Valsecchi MG, De Lorenzo P, Möricke A, Janka G, Leblanc TM, Felice M, Biondi A, Campbell M, Hann I, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood 2009; 114:3764-8; PMID:19657114; http://dx.doi.org/10.1182/blood-2009-02-204214
6. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30:41-7; PMID:11731795; http://dx.doi.org/10.1038/ng765
7. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133-43; PMID:12086872; http://dx.doi.org/10.1016/S1535-6108(02)00032-6
8. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX, de Lorenzo P, Valsecchi MG, Pieters R. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115:2835-44; PMID:20032505; http://dx.doi.org/10.1182/blood-2009-07-233049
9. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10:1107-17; PMID:12453418; http://dx.doi.org/10.1016/S1097-2765(02)00741-4
10. Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R, Dubois G, Mazo A, Croce CM, Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002; 10:1119-28; PMID:12453419; http://dx.doi.org/10.1016/S1097-2765(02) 00740-2
11. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20:5695-707; PMID:11607819; http://dx.doi.org/10.1038/sj.onc.1204639
12. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, Washburn MP, Florens L, Shilatifard A. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 2010; 24:574-89; PMID:20203130; http://dx.doi.org/10.1101/gad.1898410
13. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, Hess JL, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007; 110:4445-54; PMID:17855633; http://dx.doi.org/10.1182/blood-2007-05-090514
14. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121:167-78; PMID:15851025; http://dx.doi.org/10.1016/j.cell.2005.02.020
15. Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem 2006; 281:18059-68; PMID:16636056; http://dx.doi.org/10.1074/jbc.M601903200
16. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 2006; 75:243-69; PMID:16756492; http://dx.doi.org/10.1146/annurev.biochem.75.103004. 142422
17. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20:66-78; PMID:21741597; http://dx.doi.org/10.1016/j.ccr.2011.06.010
18. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, Croce CM, Nakamura T, Canaani E, Young RA. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008; 22:3403-8; PMID:19141473; http://dx.doi.org/10.1101/gad.1741408
19. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14:355-68; PMID:18977325; http://dx.doi.org/10.1016/j.ccr.2008.10.001
20. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222-31; PMID:11902577; http://dx.doi.org/10. 1038/35106065
21. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69; PMID:10499802; http://dx.doi.org/10.1016/S0092-8674(00)81519-6
22. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35:531-9; PMID:10492624; http://dx.doi.org/10.1016/S0959-8049(99) 00292-0
23. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30:630-41; PMID:16236519; http://dx.doi.org/10.1016/j.tibs. 2005.09.005
24. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73-87; PMID:11960696
25. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10. 1038/nrc2602
26. Bueno C, Catalina P, Melen GJ, Montes R, Sánchez L, Ligero G, García-Pérez JL, Menendez P. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis 2009; 30:1628-37; PMID:19587093; http://dx.doi.org/10.1093/ carcin/bgp169
27. Bueno C, Ayllón V, Montes R, Navarro-Montero O, Ramos-Mejia V, Real PJ, Romero-Moya D, Araúzo-Bravo MJ, Menendez P. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs. Blood 2013; 121(S1-3):3867-78, S1-3; PMID:23479570; http://dx.doi.org/10.1182/blood-2012-11-470146
28. Montes R, Ayllón V, Gutierrez-Aranda I, Prat I, Hernández-Lamas MC, Ponce L, Bresolin S, Te Kronnie G, Greaves M, Bueno C, et al. Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 2011; 117:4746-58; PMID:21389315; http://dx.doi.org/10.1182/blood-2010-12-322230
29. Montes R, Ayllón V, Prieto C, Bursen A, Prelle C, Romero-Moya D, Real PJ, Navarro-Montero O, Chillón C, Marschalek R, et al. Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia 2013; PMID:24240202; http://dx.doi.org/10.1038/leu.2013.346
30. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104:1862-8; PMID:21610706; http://dx.doi.org/10.1038/bjc.2011.177
31. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O'Dwyer PJ, Schwartz GK. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18:568-76; PMID:22090362; http://dx.doi.org/10.1158/1078-0432.CCR-11-0509
32. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597-607; PMID:22383795; http://dx.doi.org/10.1182/blood-2011-10-388298
33. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, Chen I, Schwartz G. Treatment of growing teratoma syndrome. N Engl J Med 2009; 360:423-4; PMID:19164198; http://dx.doi.org/10.1056/NEJMc0808558
34. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38; PMID:15542782
35. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007; 110:2075-83; PMID:17537993; http://dx.doi.org/10.1182/blood-2007-02-071266
36. Ericson KK, Krull D, Slomiany P, Grossel MJ. Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes. Mol Cancer Res 2003; 1:654-64; PMID:12861051
37. Jones R, Ruas M, Gregory F, Moulin S, Delia D, Manoukian S, Rowe J, Brookes S, Peters G. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6. Cancer Res 2007; 67:9134-41; PMID:17909018; http://dx.doi.org/10.1158/0008-5472.CAN-07-1528
38. Bryja V, Pacherník J, Vondrácek J, Soucek K, Cajánek L, Horvath V, Holubcová Z, Dvorák P, Hampl A. Lineage specific composition of cyclin D-CDK4/CDK6-p27 complexes reveals distinct functions of CDK4, CDK6 and individual D-type cyclins in differentiating cells of embryonic origin. Cell Prolif 2008; 41:875-93; PMID:19040567; http://dx.doi.org/10.1111/j. 1365-2184.2008.00556.x
39. Hu MG, Deshpande A, Enos M, Mao D, Hinds EA, Hu GF, Chang R, Guo Z, Dose M, Mao C, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res 2009; 69:810-8; PMID:19155308; http://dx.doi.org/10.1158/0008-5472.CAN-08-2473
40. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A 2012; 109:5028-33; PMID:22396593; http://dx.doi.org/10. 1073/pnas.1202258109
41. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012; 120:1107-17; PMID:22677129; http://dx.doi.org/10.1182/blood-2011-11-394932
42. Nordling CO. A new theory on cancer-inducing mechanism. Br J Cancer 1953; 7:68-72; PMID:13051507; http://dx.doi.org/10.1038/bjc.1953.8
43. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820-3; PMID:5279523; http://dx.doi.org/10. 1073/pnas.68.4.820
44. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995; 378:505-8; PMID:7477409; http://dx.doi.org/10.1038/378505a0
45. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106:2484-90; PMID:15956279; http://dx.doi.org/10.1182/blood-2004-09-3667
46. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207-10; PMID:11752295; http://dx.doi.org/10.1093/nar/30.1.207
47. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125-34; PMID:19138562; http://dx.doi.org/10.1016/S1470-2045(08)70339-5
48. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101:1270-6; PMID:12406912; http://dx.doi.org/10.1182/blood-2002-05-1600
49. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW, Hählen K, Veerman AJ. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76:2327-36; PMID:2257305
50. Brouwer RW, van den Hout MC, Grosveld FG, van Ijcken WF. NARWHAL, a primary analysis pipeline for NGS data. Bioinformatics 2012; 28:284-5; PMID:22072383; http://dx.doi.org/10.1093/bioinformatics/btr613
51. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, Vornlocher HP, Nordheim A. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003; 101:3157-63; PMID:12480707; http://dx.doi.org/10.1182/blood-2002-05-1589